BR0303571A - Agente para prevenir ou tratar doenças causadas pela expressão de enos - Google Patents
Agente para prevenir ou tratar doenças causadas pela expressão de enosInfo
- Publication number
- BR0303571A BR0303571A BR0303571-9A BR0303571A BR0303571A BR 0303571 A BR0303571 A BR 0303571A BR 0303571 A BR0303571 A BR 0303571A BR 0303571 A BR0303571 A BR 0303571A
- Authority
- BR
- Brazil
- Prior art keywords
- agent
- enos
- diseases caused
- preventing
- ococh3
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
- C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"AGENTE PARA PREVENIR OU TRATAR DOENçAS CAUSADAS PELA EXPRESSãO DE eNOS". A presente invenção fornece um agente terapêutico seguro com efeitos adversos desprezíveis, o qual ativa ENOS, de tal modo que ela funcione idealmente, e desta forma, trata ou previne doenças ou condições patológicas causadas por uma condição na qual o produto da expressão do gene de eNOS não apresenta sua função apropriada. Mais especificamente, a presente invenção refere-se a um agente para tratar ou prevenir doenças ou condições patológicas causadas por um aumento em eNOS, o qual contém, como um ingrediente ativo, um composto representado pela seguinte fórmula (I) ou um seu sal farmaceuticamente aceitável: onde cada um entre R^ 1^ e R^ 2^ representa um átomo de hidrogênio, ou R^ 1^ e R^ 2^ juntos formam uma ligação simples, e quando cada um entre R^ 1^ e R^ 2^ representa simultaneamente um átomo de hidrogênio, R^ 3^ representa -CH(OH)CH(OH)CH~ 3~, -CH(OCOCH~ 3~)CH(OCOCH~ 3~)CH~ 3~, -CH~ 3~ -CH~ 2~OH ou um grupo fenila, e quando R^ 1^ e R^ 2^ juntos formam uma ligação simples, R^ 3^ representa -COCH(OH)CH~ 3~.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002082159A JP4836388B2 (ja) | 2002-03-22 | 2002-03-22 | ｅＮＯＳ発現に起因する疾患の予防または治療薬 |
| PCT/JP2003/003428 WO2003080063A1 (fr) | 2002-03-22 | 2003-03-20 | Moyens preventifs ou therapeutiques pour les maladies provoquees par l'expression de enos |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0303571A true BR0303571A (pt) | 2004-04-20 |
Family
ID=28449137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0303571-9A BR0303571A (pt) | 2002-03-22 | 2003-03-20 | Agente para prevenir ou tratar doenças causadas pela expressão de enos |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20040198738A1 (pt) |
| EP (1) | EP1488793A4 (pt) |
| JP (1) | JP4836388B2 (pt) |
| KR (1) | KR20040090400A (pt) |
| CN (1) | CN1330309C (pt) |
| BR (1) | BR0303571A (pt) |
| CA (1) | CA2451516A1 (pt) |
| WO (1) | WO2003080063A1 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040053953A1 (en) | 2002-03-18 | 2004-03-18 | Schering Corporation | Treatment of chemokine mediated diseases |
| AU2004291149C1 (en) * | 2003-11-17 | 2021-01-21 | Biomarin Pharmaceutical Inc. | Methods and Compositions for the Treatment of Metabolic Disorders |
| EP1550451A1 (en) * | 2003-12-29 | 2005-07-06 | Boehringer Ingelheim International GmbH | Composition comprising an aqueous extract of red vine leaves and a diuretic for the treatment of chronic venous insufficiencies |
| ES2393785T3 (es) * | 2004-05-11 | 2012-12-28 | Daiichi Sankyo Company, Limited | Remedios para hiperfenilalaninemia sensible a BH4 |
| TW200719896A (en) * | 2005-04-18 | 2007-06-01 | Astrazeneca Ab | Combination product |
| US20100234385A1 (en) * | 2006-03-20 | 2010-09-16 | Kaneka Corporation | Compsition Containing Biopterin and Method for Using The Same |
| EP2456432B1 (en) | 2009-07-22 | 2024-02-28 | University of Massachusetts | Compositions to reduce oxidative stress |
| US9216178B2 (en) | 2011-11-02 | 2015-12-22 | Biomarin Pharmaceutical Inc. | Dry blend formulation of tetrahydrobiopterin |
| JP6809781B2 (ja) * | 2015-11-18 | 2021-01-06 | 白鳥製薬株式会社 | プテリン誘導体又はその塩 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4418097A1 (de) * | 1994-05-24 | 1995-11-30 | Cassella Ag | Verwendung von Tetrahydropteridin-Derivaten als Hemmstoffe der NO-Synthase |
| KR100650962B1 (ko) * | 1996-08-30 | 2007-07-18 | 다이이치 아스비오파마 가부시키가이샤 | 질소산화물합성효소(nos)의기능저하에의해유발되는질환의예방또는치료제 |
| JP4842415B2 (ja) * | 1996-08-30 | 2011-12-21 | 第一三共株式会社 | Ｎｏｓの機能低下が寄与する疾患の予防または治療剤 |
| CN1244328C (zh) * | 1996-08-30 | 2006-03-08 | 第一阿斯比奥制药株式会社 | 治疗或预防由nos功能减退诱发的疾病的药物 |
| US5929062A (en) * | 1997-06-19 | 1999-07-27 | University Of Western Ontario | Oxysterol inhibition of dietary cholesterol uptake |
| US6544994B2 (en) * | 2000-06-07 | 2003-04-08 | Eprov Ag | Pharmaceutical preparation for treating or preventing cardiovascular or neurological disorders by modulating of the activity of nitric oxide synthase |
-
2002
- 2002-03-22 JP JP2002082159A patent/JP4836388B2/ja not_active Expired - Fee Related
-
2003
- 2003-03-20 CN CNB038005662A patent/CN1330309C/zh not_active Expired - Fee Related
- 2003-03-20 EP EP03715388A patent/EP1488793A4/en not_active Ceased
- 2003-03-20 US US10/481,385 patent/US20040198738A1/en not_active Abandoned
- 2003-03-20 CA CA002451516A patent/CA2451516A1/en not_active Abandoned
- 2003-03-20 WO PCT/JP2003/003428 patent/WO2003080063A1/ja active Application Filing
- 2003-03-20 KR KR10-2003-7017283A patent/KR20040090400A/ko not_active Application Discontinuation
- 2003-03-20 BR BR0303571-9A patent/BR0303571A/pt not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1533277A (zh) | 2004-09-29 |
| EP1488793A1 (en) | 2004-12-22 |
| CA2451516A1 (en) | 2003-10-02 |
| KR20040090400A (ko) | 2004-10-22 |
| JP4836388B2 (ja) | 2011-12-14 |
| JP2003277265A (ja) | 2003-10-02 |
| US20040198738A1 (en) | 2004-10-07 |
| WO2003080063A1 (fr) | 2003-10-02 |
| EP1488793A4 (en) | 2008-07-30 |
| CN1330309C (zh) | 2007-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1109242T1 (el) | Θεραπευτικοι παραγοντες χρησιμοι για θεραπεια πονου | |
| DE69939651D1 (de) | Behandlung hyperproliferativer erkrankungen | |
| BRPI0408784A (pt) | método para usar um composto | |
| CY1111951T1 (el) | Φαινυλο-καρβοξαμιδικες ενωσεις χρησιμες για την αντιμετωπιση πονου | |
| BR0111980A (pt) | Amina substituìda, composto protegido, métodos para tratar um paciente que tenha ou para prevenir que um paciente contraia uma doença ou condição, para inibir a atividade da beta-secretase, para inibir a clivagem da proteìna precursora de amilóide (app), para inibir a produção do peptìdeo beta amilóide (a beta) em uma célula, para inibir a produção de placa beta0amilóide em um animal, e para tratar ou prevenir uma doença compreendendo depósitos de beta-amilóide no cérebro, composição método para produzir um complexo de beta-secretase, conjunto, e, uso de amina substituìda | |
| AR044007A1 (es) | Metodos para el tratamiento de la enfermedad de parkinson | |
| BRPI0607536A2 (pt) | tratamento de dor | |
| DE60316779D1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
| BRPI0415167A (pt) | composto de amina como ligandos de canal de ìon e usos dos mesmos | |
| BR0314699A (pt) | Composto, composição e métodos para o tratamento da dor e para inibição da função vr1 em uma célula | |
| EA200500893A1 (ru) | Трициклические соединения, представляющие собой ингибиторы протеинкиназ, для увеличения эффективности противоопухолевых агентов и лучевой терапии | |
| BR0314943A (pt) | Inibidores da proteìna reguladora da condutância transmembrana da fibrose cìstica e usos destes | |
| BRPI0409624A (pt) | 2-hidróxi-3-diaminoalcanos de benzamida | |
| BR0207316A (pt) | Derivados de epotilona para o tratamento de tumores refratários | |
| BR0303571A (pt) | Agente para prevenir ou tratar doenças causadas pela expressão de enos | |
| WO2004110380A3 (en) | Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents | |
| DE69512589T2 (de) | Behandlung von durch Talgdrüse verursachten Erkrankungen mit Inhibitoren der Acyl CoA Cholesterin Acyltransferase | |
| BRPI0409796A (pt) | uso de dipiridamol ou mopidamol para tratamento e prevenção de doenças tromboembolìticas e distúrbios provocados pela formação excessiva de trombina e/ou pela expressão elevada de receptores de trombina | |
| WO2004110151A8 (en) | Treatment of cancer with active vitamin d compounds in combination with radiotherapeutic agents and treatments | |
| RU94044356A (ru) | Применение 2-фенил-3-ароилбензотиофенов для увеличения экспрессии тромбомодулина для ингибирования тромботического расстройства, для увеличения активации протеина с | |
| BRPI0417902A (pt) | piperazinas úteis no tratamento da dor | |
| BR0307411A (pt) | Ligantes alfa2delta para tratar zumbidos | |
| BR0317289A (pt) | Método para tratar distúrbios do movimento usando derivados do ácido barbitúrico | |
| BR9707303A (pt) | Agentes terapêuticos para asma | |
| IL163374A (en) | Urea derivatives for treatment or prevention of disorders of the eye |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25F | Entry of change of name and/or headquarter and transfer of application, patent and certif. of addition of invention: change of name on requirement |
Owner name: DAIICHI SUNTORY PHARMA CO., LTD. (JP) Free format text: A FIM DE ATENDER O SOLICITADO NA PETICAO DE ALTERACAO DE NOME NO 020050146800/RJ DE 14/12/2005, QUEIRA APRESENTAR A TRADUCAO DO DOCUMENTO DE ALTERACAO DE NOME. |
|
| B25D | Requested change of name of applicant approved |
Owner name: DAIICHI ASUBIO PHARMA CO., LTD. (JP) Free format text: ALTERADO DE: DAIICHI SUNTORY PHARMA CO., LTD. |
|
| B25G | Requested change of headquarter approved |
Owner name: DAIICHI ASUBIO PHARMA CO., LTD. (JP) Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020050146800/RJ DE 14/12/2005. |
|
| B25D | Requested change of name of applicant approved |
Owner name: ASUBIO PHARMA CO., LTD. (JP) Free format text: ALTERADO DE: DAIICHI ASUBIO PHARMA CO., LTD. |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: DAIICHI SANKYO COMPANY, LIMITED (JP) Free format text: TRANSFERIDO POR FUSAO DE: ASUBIO PHARMA CO., LTD. |
|
| B08L | Patent application lapsed because of non payment of annual fee [chapter 8.12 patent gazette] |
Free format text: REFERENTE AO NAO RECOLHIMENTO DAS 9A, 10A E 11A ANUIDADES. |
|
| B08I | Publication cancelled [chapter 8.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 8.12 NA RPI NO 2258 DE 15/04/2014 POR TER SIDO INDEVIDA. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 9A, 10A, 11A, 12A, 13A, 14A, 15A, 16A E 17A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2602 DE 17-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |